Skip to main content

Oramed Pharmaceuticals Inc.

ORMP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001176309

In the last 90 days, Oramed Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 84 institutions reported holding it in 13F filings for Q2 2026, worth $80.7M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Oramed Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $942.2K in total
Insiders trading
2
Net value
−$942.2K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Oramed Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Oramed Pharmaceuticals Inc.
NameTitleLast reported holdingLast filingFilings, past year
Kidron NadavPresident and CEO4,140,505Sep 25, 20266
Hexter JoshuaCOO & CBO1,358,130Sep 25, 20265
Kidron MiriamChief Scientific Officer1,550,554Sep 25, 20266
Gabay AvrahamChief Financial Officer881,076Sep 25, 20265
Mayer ArieDirector168,009Jan 5, 20261
Shapiro BenjaminDirector123,220Jan 5, 20261
Reznick YehudaDirector105,180Jan 5, 20261
Aghion DanielDirector113,441Jan 2, 20261
Sank LeonardDirector134,531Jun 9, 20250
Silberman DavidChief Financial Officer366,500Jan 8, 20240
Rozov YadinDirector155,320Jan 8, 20240
Derovan NetanelChief Legal Officer149,500May 31, 20230
Rabinowitz MichaelChief Commercial Officer126,143Jan 4, 20230
Rakin KevinDirector46,661Mar 22, 20220
Friedman AviadDirector0Jan 5, 20220
Rabinowitz MichaelChief Commercial Officer109,468Jan 5, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 2, 2026 (view filing)5:00 PM ETJul 11 dayHexter JoshuaCOO & CBOSSale−137.0K$4.46−$611.4K−11.8%1.02M after
Jul 2, 2026 (view filing)5:00 PM ETJul 11 dayGabay AvrahamChief Financial OfficerSSale−73.4K$4.51−$330.7K−9.8%671.8K after
Apr 4, 2023 (view filing)Apr 3-41 dayMayer ArieDirectorPPurchase+8.81K$2.22+$19.5K+48.9%26.8K after2 lots
Mar 16, 2023 (view filing)Mar 16Same dayKidron NadavPresident and CEOPPurchase+26.0K$2.04+$53.0K+26.0%126.0K after
Mar 15, 2023 (view filing)Mar 141 dayKidron NadavPresident and CEOPPurchase+100.0K$2.01+$201.0KNew position100.0K after
Mar 15, 2023 (view filing)Mar 141 dayKidron MiriamChief Scientific OfficerSSale−100.0K$2.01−$201.0K−33.1%201.7K after
Mar 15, 2023 (view filing)Mar 13-142 daysRozov YadinDirectorPPurchase+70.0K$2.02+$141.7K+424.2%86.5K after2 lots
Jan 4, 2023 (view filing)Jan 31 dayRabinowitz MichaelChief Commercial OfficerSSale−13.3K$12.55−$167.2K−9.6%126.1K after2 lots
May 10, 2022 (view filing)Nov 1, 2021190 daysLateMayer ArieDirectorSSale−3.00K$25.60−$76.8K−100.0%0 after
Mar 22, 2022 (view filing)Mar 211 dayRakin KevinDirectorSSale−10.0K$9.41−$94.1K−17.6%46.7K after
Dec 7, 2021 (view filing)Aug 9120 daysKidron NadavPresident and CEOSSale−220.0K$20.11−$4.42M−23.0%738.2K afterAmended
Sep 20, 2021 (view filing)Sep 164 daysRakin KevinDirectorSSale−21.1K$20.99−$442.9K−27.0%57.0K after